Table of Content

Chapter 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
Chapter 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
Chapter 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
Chapter 4: FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market Size and Forecast, By Product Type
4.2. Lancing Devices and Strips
4.3. Blood-Glucose Meter
Chapter 5: FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Type-1 Diabetes
5.3. Type-2 Diabetes
Chapter 6: FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market Size and Forecast, By End User
6.2. Hospitals and Clinics
6.3. Home Care Settings
6.4. Others
Chapter 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
Chapter 8: COMPANY PROFILES
8.1. Abbott
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Roche Diagnostics
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Arysta Lifescience
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Lifescan
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Sanofi
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. AgaMatrix
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Nipro Diagnostics
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Demeditec Diagnostics
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Glucose Diagnostics
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Acon Laboratories
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments



List of Figures

LIST OF FIGURES
FIGURE 01. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET
FIGURE 10. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET,BY PRODUCT TYPE, 2022 ($MILLION)
FIGURE 11. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET,BY END USER, 2022 ($MILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET
FIGURE 19. TOP PLAYER POSITIONING, 2022
FIGURE 20. ABBOTT: NET SALES, 2020-2022*?($MILLION)
FIGURE 21. ABBOTT: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 22. ABBOTT: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 23. ROCHE DIAGNOSTICS: NET SALES, 2020-2022*?($MILLION)
FIGURE 24. ROCHE DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 25. ROCHE DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 26. ARYSTA LIFESCIENCE: NET SALES, 2020-2022*?($MILLION)
FIGURE 27. ARYSTA LIFESCIENCE: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 28. ARYSTA LIFESCIENCE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 29. LIFESCAN: NET SALES, 2020-2022*?($MILLION)
FIGURE 30. LIFESCAN: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 31. LIFESCAN: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 32. SANOFI: NET SALES, 2020-2022*?($MILLION)
FIGURE 33. SANOFI: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 34. SANOFI: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 35. AGAMATRIX: NET SALES, 2020-2022*?($MILLION)
FIGURE 36. AGAMATRIX: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 37. AGAMATRIX: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 38. NIPRO DIAGNOSTICS: NET SALES, 2020-2022*?($MILLION)
FIGURE 39. NIPRO DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 40. NIPRO DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 41. DEMEDITEC DIAGNOSTICS: NET SALES, 2020-2022*?($MILLION)
FIGURE 42. DEMEDITEC DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 43. DEMEDITEC DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 44. GLUCOSE DIAGNOSTICS: NET SALES, 2020-2022*?($MILLION)
FIGURE 45. GLUCOSE DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 46. GLUCOSE DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 47. ACON LABORATORIES: NET SALES, 2020-2022*?($MILLION)
FIGURE 48. ACON LABORATORIES: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 49. ACON LABORATORIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

List of Tables

LIST OF TABLES
TABLE 01. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 02. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 04. ABBOTT: KEY EXECUTIVES
TABLE 05. ABBOTT: COMPANY SNAPSHOT
TABLE 06. ABBOTT: OPERATING SEGMENTS
TABLE 07. ABBOTT: PRODUCT PORTFOLIO
TABLE 08. ABBOTT: KEY STRATERGIES
TABLE 09. ROCHE DIAGNOSTICS: KEY EXECUTIVES
TABLE 10. ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 11. ROCHE DIAGNOSTICS: OPERATING SEGMENTS
TABLE 12. ROCHE DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 13. ROCHE DIAGNOSTICS: KEY STRATERGIES
TABLE 14. ARYSTA LIFESCIENCE: KEY EXECUTIVES
TABLE 15. ARYSTA LIFESCIENCE: COMPANY SNAPSHOT
TABLE 16. ARYSTA LIFESCIENCE: OPERATING SEGMENTS
TABLE 17. ARYSTA LIFESCIENCE: PRODUCT PORTFOLIO
TABLE 18. ARYSTA LIFESCIENCE: KEY STRATERGIES
TABLE 19. LIFESCAN: KEY EXECUTIVES
TABLE 20. LIFESCAN: COMPANY SNAPSHOT
TABLE 21. LIFESCAN: OPERATING SEGMENTS
TABLE 22. LIFESCAN: PRODUCT PORTFOLIO
TABLE 23. LIFESCAN: KEY STRATERGIES
TABLE 24. SANOFI: KEY EXECUTIVES
TABLE 25. SANOFI: COMPANY SNAPSHOT
TABLE 26. SANOFI: OPERATING SEGMENTS
TABLE 27. SANOFI: PRODUCT PORTFOLIO
TABLE 28. SANOFI: KEY STRATERGIES
TABLE 29. AGAMATRIX: KEY EXECUTIVES
TABLE 30. AGAMATRIX: COMPANY SNAPSHOT
TABLE 31. AGAMATRIX: OPERATING SEGMENTS
TABLE 32. AGAMATRIX: PRODUCT PORTFOLIO
TABLE 33. AGAMATRIX: KEY STRATERGIES
TABLE 34. NIPRO DIAGNOSTICS: KEY EXECUTIVES
TABLE 35. NIPRO DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 36. NIPRO DIAGNOSTICS: OPERATING SEGMENTS
TABLE 37. NIPRO DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 38. NIPRO DIAGNOSTICS: KEY STRATERGIES
TABLE 39. DEMEDITEC DIAGNOSTICS: KEY EXECUTIVES
TABLE 40. DEMEDITEC DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 41. DEMEDITEC DIAGNOSTICS: OPERATING SEGMENTS
TABLE 42. DEMEDITEC DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 43. DEMEDITEC DIAGNOSTICS: KEY STRATERGIES
TABLE 44. GLUCOSE DIAGNOSTICS: KEY EXECUTIVES
TABLE 45. GLUCOSE DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 46. GLUCOSE DIAGNOSTICS: OPERATING SEGMENTS
TABLE 47. GLUCOSE DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 48. GLUCOSE DIAGNOSTICS: KEY STRATERGIES
TABLE 49. ACON LABORATORIES: KEY EXECUTIVES
TABLE 50. ACON LABORATORIES: COMPANY SNAPSHOT
TABLE 51. ACON LABORATORIES: OPERATING SEGMENTS
TABLE 52. ACON LABORATORIES: PRODUCT PORTFOLIO
TABLE 53. ACON LABORATORIES: KEY STRATERGIES